Josh Arnold Investment Consultant LLC Acquires New Position in The Oncology Institute, Inc. $TOI

Key Points

• Josh Arnold Investment Consultant LLC has acquired a new position in The Oncology Institute, Inc. ($TOI), purchasing approximately 1,988,900 shares valued at $2.27 million.
• A number of other institutional investors, including Citizens Financial Group and WealthShield Partners, have also initiated new stakes in Oncology Institute, reflecting increased interest in the stock.
• Analyst ratings for $TOI remain favorable, with a consensus rating of "Buy" and an average price target of $7.00, as per recent research reports.

Josh Arnold Investment Consultant LLC bought a new position in The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,988,900 shares of the company's stock, valued at approximately $2,267,000. Oncology Institute accounts for 1.9% of Josh Arnold Investment Consultant LLC's holdings, making the stock its 7th largest holding. Josh Arnold Investment Consultant LLC owned approximately 2.63% of Oncology Institute as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of TOI. Jane Street Group LLC lifted its stake in shares of Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after acquiring an additional 109,769 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock worth $56,000 after purchasing an additional 12,000 shares during the period. XTX Topco Ltd raised its position in shares of Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after purchasing an additional 18,448 shares during the period. Citizens Financial Group Inc. RI bought a new position in Oncology Institute in the 1st quarter worth approximately $71,000. Finally, WealthShield Partners LLC bought a new position in Oncology Institute in the 1st quarter worth approximately $80,000. Hedge funds and other institutional investors own 36.86% of the company's stock.

Oncology Institute Trading Down 0.6%

NASDAQ:TOI traded down $0.02 during trading hours on Tuesday, hitting $3.23. 1,113,568 shares of the stock were exchanged, compared to its average volume of 1,482,345. The company's 50 day moving average is $3.45 and its two-hundred day moving average is $2.52. The company has a market capitalization of $302.01 million, a P/E ratio of -4.75 and a beta of 0.10. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $4.50. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 14.58.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. BTIG Research initiated coverage on Oncology Institute in a research note on Thursday, May 15th. They set a "buy" rating and a $7.00 price target for the company. B. Riley initiated coverage on Oncology Institute in a report on Wednesday, July 16th. They set a "buy" rating and a $6.00 price objective for the company. Finally, Noble Financial started coverage on shares of Oncology Institute in a research report on Wednesday, July 23rd. They set an "outperform" rating and a $8.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. Based on data from MarketBeat, Oncology Institute currently has an average rating of "Buy" and an average price target of $7.00.

Insider Transactions at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 6,018,168 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $3.09, for a total transaction of $18,596,139.12. Following the completion of the transaction, the director directly owned 7,932,389 shares in the company, valued at $24,511,082.01. This represents a 43.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 8.50% of the company's stock.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.